# Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy Volunteers

> **NCT02249416** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Tipranavir (TPV) low
- **DRUG:** Ritonavir (RTV) low
- **DRUG:** Tipranavir (TPV) high
- **DRUG:** Ritonavir (RTV) high
- **DRUG:** Zidovudine

## Key facts

- **NCT ID:** NCT02249416
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2002-02
- **Final completion:** —
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2014-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02249416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02249416, "Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy Volunteers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02249416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*